Welcome to our dedicated page for Enzo Biochem SEC filings (Ticker: ENZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Enzo Biochem funds breakthrough molecular diagnostics and protects its patent estate means wading through dense SEC documents. Revenue mixes shift between reagent sales and technology licensing, R&D outlays rise and fall with pipeline milestones, and FDA-related 8-Ks can appear without notice—critical data that’s often buried across hundreds of pages.
Stock Titan solves this headache. Our feed captures every Enzo Biochem quarterly earnings report 10-Q filing, proxy statement executive compensation table, and 8-K material event the moment EDGAR releases them, then layers on AI-powered summaries that explain the numbers in plain language. Need Enzo Biochem insider trading Form 4 transactions as they happen? Real-time alerts arrive with context so you instantly see whether executives are buying or selling.
Dive into an annual report 10-K simplified view to find year-over-year R&D spend, royalty income from proprietary probes, and reserves for patent litigation. Compare segment margins side-by-side, export key figures, and answer questions like “What does Enzo Biochem report in its SEC filings?”—all without scrolling through footnotes.
- Enzo Biochem Form 4 insider transactions real-time monitoring
- Understanding Enzo Biochem SEC documents with AI highlights
- Enzo Biochem earnings report filing analysis across quarters
- Full-text search of Enzo Biochem proxy statement executive compensation details
- Enzo Biochem 8-K material events explained for FDA updates and patent rulings
Whether you’re modeling assay revenue or watching licensing trends, our comprehensive, AI-enhanced SEC feed equips you to act quickly and confidently—no jargon, no guesswork, just the insights that move Enzo Biochem’s stock.
Enzo Biochem, Inc. (ENZ) entered into and completed a merger in which Bethpage Merger Sub merged into Enzo, and Enzo became a wholly owned subsidiary of Bethpage Parent.
At the effective time on August 20, 2025, each outstanding share was converted into the right to receive $0.70 in cash per share (subject to withholding). Vested restricted stock units held by directors or vested-but-unsettled RSUs were converted into a cash payment equal to the number of underlying shares multiplied by $0.70. Unvested RSUs and all outstanding options were canceled without consideration. As a result, the reporting persons state they no longer beneficially own any Enzo securities and ceased to own more than 5% of the class.
Enzo Biochem, Inc. filed an S-8 post-effective amendment covering previously filed registration statements for shares issuable under various employee benefit and equity compensation plans. The filing lists multiple prior registration statements dating from 1983 through 2021 that pertain to aggregate share amounts under plans including the 1994 Plan, 1999 Plan, 2011 Incentive Plan, Profit Sharing Plan and inducement awards. The filing is signed by Chief Financial Officer Patricia Eckert.
Enzo Biochem, Inc. filed an S-8 post-effective amendment covering previously filed employee benefit and equity compensation registration statements. The filing lists multiple historical registrations that together authorize issuance under various plans, including registered amounts of 988,951, 950,000, 1,000,000, 2,000,000, 3,000,000, 1,000,000, 2,000,000, 1,000,000, 4,000,000 and an aggregate 960,000 shares tied to inducement awards. The document is a routine update that consolidates past registration statements for employee plans and is signed by Patricia Eckert, Chief Financial Officer.
Enzo Biochem, Inc. filed an S-8 post-effective amendment covering prior employee equity registration statements. The filing lists a series of historic registrations that together cover multiple equity plans, including a 4,000,000-share registration under the 2011 Incentive Plan and a separate 960,000-share registration
Enzo Biochem, Inc. (ENZ) filed an S-8 post-effective amendment that catalogs prior employee equity registration statements covering multiple stock plans. The filing lists historic registrations dating from
Enzo Biochem, Inc. filing confirms classification as a non-accelerated filer and smaller reporting company and lists prior SEC registration statements related to employee benefit and equity compensation plans spanning 1983 through 2021. The filing enumerates multiple registration statement numbers and aggregate share amounts registered under various plans, and is signed by the Chief Financial Officer, Patricia Eckert.
Enzo Biochem, Inc. filed an S-8 post-effective submission that lists prior registration statements covering shares of its common stock issuable under various employee benefit and equity incentive plans. The filing enumerates multiple prior registration statements (1983, 1992, 1994, 1995, 1999, 2002, 2005, 2011, 2014, 2018, 2020, 2021) and specifies aggregate share amounts for several plans. The document is signed by Patricia Eckert, Chief Financial Officer.
FAQ
What is the current stock price of Enzo Biochem (ENZ)?
What is the market cap of Enzo Biochem (ENZ)?
